CONFERENCE UPDATE: AHA 2022

Olpasiran effectively lowers Lp(a) level in patients with established ASCVD: The OCEAN(a)-DOSE trial

CARDIOLOGY
19 Jan 2023

Get access to our exclusive articles.
Related Articles

DECLARE-TIMI 58: Cutting heart failure risk with dapagliflozin

Ever since the United States Food and Drug Administration (FDA) issued the mandate for conducting cardiovascular outcomes trials (CVOTs) with type 2 diabetes drugs, eight CVOTs have already been completed,

CARDIOLOGY DIABETES & ENDOCRINOLOGY
28 Feb 2019